As of December 2024, the Ozempic litigation has progressed significantly. In February 2024, the U.S. Judicial Panel on Multidistrict Litigation consolidated numerous lawsuits into MDL-3094 in the Eastern District of Pennsylvania, with Judge Gene E.K. Pratter presiding.
These Ozempic lawsuits allege that Novo Nordisk failed to adequately warn users about severe gastrointestinal side effects, including gastroparesis and bowel obstruction. Plaintiffs report experiencing persistent nausea, vomiting, and, in severe cases, the necessity for surgical interventions like colon removal.
The growing number of lawsuits underscores ongoing concerns about the medication’s potential risks. What is the current status of Ozempic lawsuits? The number of cases in the MDL has grown substantially throughout 2024, reflecting these increasing concerns. In October 2024, Judge Pratter made a critical decision in the pre-discovery phase, denying the plaintiffs’ motion to require the defendants to turn over specific marketing materials early in the case.
The court has scheduled a series of status conferences throughout 2025 to address early motions to dismiss and discovery focused on issues expected to impact many claims. Novo Nordisk continues to defend the safety and efficacy of Ozempic, asserting that the drug is safe when used as directed.
1-800-870-8910